SCHEMBL20570945

SCHEMBL20570945

CC(C)(C)OC(=O)N1CCN(Cc2ccc(Cl)c(Br)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 1/20 0.52
EGLN1 Q9GZT9 1/20 0.52
FAAH O00519 8/20 0.48
KDM1A O60341 1/20 0.48
GPR183 P32249 1/20 0.46
PLA2G7 Q13093 1/20 0.46
MGLL Q99685 1/20 0.46
ABHD6 Q9BV23 1/20 0.46
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45
IDO2 Q6ZQW0 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK8 P45983 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5030322 0.89 KDM1A (0.57) VEGFAEGLN1FAAHKDM1AGPR183
SCHEMBL3596539 0.89 FAAH (0.56) VEGFAEGLN1FAAH
SCHEMBL20570511 0.88 SIGMAR1 (0.47) VEGFAEGLN1KDM1AMEN1KMT2A
SCHEMBL20668704 0.87 VEGFA (0.55) VEGFAEGLN1FAAHKDM1APLA2G7
SCHEMBL18087154 0.87 LMNA (0.56) VEGFAEGLN1FAAHGPR183IDO1
SCHEMBL4185470 0.86 VEGFA (0.47) VEGFAEGLN1FAAHIDO1TDO2
SCHEMBL5481602 0.86 VEGFA (0.52) VEGFAEGLN1FAAHKDM1APLA2G7
SCHEMBL1433245 0.85 POLB (0.58) VEGFAEGLN1FAAHGPR183PLA2G7
SCHEMBL1006605 0.84 VEGFA (0.55) VEGFAEGLN1FAAHKDM1APLA2G7
SCHEMBL18064777 0.84 IDO1 (0.46) VEGFAEGLN1FAAHPLA2G7MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 EP disclosed
CN-110678177-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-06-13 CN disclosed
US-11149037-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2021-10-19 US disclosed
EP-3634404-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-15 EP disclosed
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-03-19 US disclosed
CN-110678177-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
WO-2018217809-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149037-B2 Pyrazole MAGL inhibitors MAGI3, MAG, PYM1 VEGFA 4884/4885EGLN1 2785/4885FAAH 112/4885
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS MAGI3, MAG, PYM1 VEGFA 4884/4885EGLN1 2785/4885FAAH 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.